Earnings watch · TLX · Healthcare

Telix Pharmaceuticals Limited (TLX) heads into June 25 earnings with mixed technical backing

The radiopharmaceuticals developer has risen across recent weekly windows, but relative strength remains negative into the report.

Telix Pharmaceuticals Limited
Latest10.09 USD
1W move5.5%
Volume1.2x
TrendActive
Radiopharmaceutical biotechnology lab with market data screens ahead of Telix Pharmaceuticals earnings.

Market update

What happened

Telix Pharmaceuticals Limited (TLX) last closed at 10.09 USD ahead of its scheduled June 25 earnings report, with the earnings calendar showing a -0.01 USD estimate for the quarter ended March 31.

The 52-week weekly price path shows an active trend, while Market Dynamics provides modest confirmation at 0.39. The setup is not one-sided: relative strength is still negative at -17.3, and the latest weekly volume ran 1.21 times the 13-week average.

Continue your research

Explore TLX across Sharemaestro

These links are shown because current Sharemaestro data is available for this company.

Interactive chartReview weekly price, Trend Line, Fair Value, volume and Relative Strength.Full weekly reportOpen the full company report, financial profile and peer comparison.Technical analysisExamine support, resistance, momentum and the current trend readings.Stage analysisSee whether the stock is basing, advancing, distributing or declining.Trend historyReview how long the current trend has persisted and where it has changed.Sector comparisonCompare sector returns, breadth, leaders and weaker areas.Industry comparisonSee how this company’s industry is performing across its members.Company factorsCompare value, quality, growth, momentum and financial strength.News sentimentSee the balance, quality and freshness of recent company coverage.Buying and selling pressureReview longer-term accumulation, distribution and reversal readings.EarningsReview report dates, estimates, past results and earnings surprises.Short interestReview short positioning, crowding and possible squeeze risk.

TLX coverage

Evidence context